Scintigraphic evaluation of dogs with acute synovitis after treatment with glucosamine hydrochloride and chondroitin sulfate

American Journal of Veterinary Research

Volumn 60, Issue 12, 1999, Pages 1552-1557

  Canapp Jr , Sherman O ^a,b   McLaughlin Jr , Ronald M ^a,c   Hoskinson, James J ^a   Roush, James K ^a   Butine, Michael D ^a,d  

^a KANSAS STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c Indianapolis Veterinary Specialists   (United States)

^d AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN SULFATE; CHYMOPAPAIN; GLUCOSAMINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOG DISEASE; INTRAARTICULAR DRUG ADMINISTRATION; JOINT SCINTISCANNING; NONHUMAN; ORAL DRUG ADMINISTRATION; SYNOVITIS; WRIST;

ADMINISTRATION, ORAL; ANIMALS; CHONDROITIN SULFATES; CHYMOPAPAIN; DOGS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GLUCOSAMINE; LAMENESS, ANIMAL; SYNOVITIS;

ANIMALIA; CANIS FAMILIARIS;

EID: 0344240121     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Johnston SA. Osteoarthritis: joint anatomy, physiology, and pathobiology. Vet Clin North Am 1997;27:699-701.
2. Bennett D. Joint disease. In: Chandler EA, Sutton JB, Thompson DJ, eds. Canine medicine and therapeutics. 2nd ed, Oxford, England: Blackwell, 1984;167-205.
3. McIlwraith CW, Van Sickle DC. Experimentally induced arthritis of the equine carpus: histologic and histochemical changes in the articular cartilage, Am J Vet Res 1981;42:209-217.
4. Boulay JP, DeAngelis M, Kincaid SA, et al. Medical therapy of osteoarthritis in dogs. Compend Contin Educ Pract Vet(suppl) 1995;5-18.
5. McNamara, PS. Slow-acting disease-modifying osteoarthritis agents. Vet Clin North Am 1997;27:863-881.
6. Manley PA. Treatment of degenerative joint disease. In: Bonagura JD, Kirk RW, eds. Kirk's current veterinary therapy XII. Philadelphia: WB Saunders Co, 1995;1196-1199.
7. Gonzalez E, de la Cruz C, de Nicholas R, et al. Long-term effect on nonsteriodal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. Agents Actions 1994;41:171-178.
8. Hulse D. Treatment methods for pain in the osteoarthritic patient. Vet Clin North Am 1998;28:361-374.
9. Serni U. Profile of glucosamine sulfate as an example of slow-acting drugs in osteoarthritis. Rev Esp Rheumatol 1993;20(suppl):222.
10. Ghosh P, Smith M, Wells C. Second-line agents in osteoarthritis. In: Dixon JS, Furst DE, eds. Second-line agents in the treatment of rheumatic diseases. New York: Marcel Dekker, Inc, 1992;363.
11. Bassler C, Henrotin Y, Franchiment P. In vitro evaluation of drugs proposed as chondroprotective agents. Int J Tissue React 1992;14:231-241.
12. Hannan N, Gosh P, Bellenger C, et al. Systemic administration of glycosaminoglycan polysulphate (Arteparon) provides partial protection of articular cartilage from damage produced by meniscectomy in the canine. J Orthop Res 1987;5:47-59.
13. Bucci LR. Chondroprotective agents: glucosamine salts and chondroitin sulfates. Townsend Lett Doctors, 1994;52-54.
14. Todhunter RJ, Lust G. Polysulfated glycosaminoglycan in the treatment of osteoarthritis. J Am Vet Med Assoc 1994;204: 1245-1251.
15. Paroli E, Antonilli L, Biffoni M. Pharmacological approach to glycosaminoglycans. Drugs Exp Clin Res 1991;17:9-20.
16. Harmand MF, Jana JV. Effects of S-adenosylmethionine on human articular chondrocyte differentiation. Am J Med 1987;83: 48-53.
17. Glorioso S, Todesco S, Mazzi A, et al. Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis. Int J Clin Pharmacol Res 1985;1:39-49.
18. Padova CD. S-Adenoslymethionine in the treatment of osteoarthritis. Review of clinical studies. Am J Med 1987;83:60-65.
19. Morcelling R, Giordano N. Double-blind multicentre study of the activity of S-adenosyl-methionine in hip and knee osteoarthritis. Carr Thera Res 1985;37:82-94.
20. Schumacher HR. Osteoarthritis: the clinical picture, pathogenesis, and management with studies on a new therapeutic agent, S-adenosylmethionine. Am J Med 1987;83(suppl);1-4.
21. Nicolle C. Randomization and the mechanics of treatment masking. In: Meinert CL, ed. Clinical trials, design, conduct and analysis. New York: Oxford University Press Inc, 1986;99.
22. Williams JM, Downey C, Thonar EJ-MA. Increase in levels of serum keratan sulfate following cartilage proteoglycan degradation in the rabbit knee joint. Arthritis Rheum 1988;31:557-560.
23. Brandt KD, Thonar E J. Lack of association between serum keratan sulfate concentrations and cartilage changes of osteoarthritis after transection of the anterior cruciate ligament in the dog. Arthritis Rheum 1989;32:647-651.
24. Williams JM, Uebchart D, Thonar EJ. Alteration and recovery of the spatial orientation of the collagen network of articular cartilage in adolescent rabbits following intra-articular chymopapain injection. Connect Tissue Res 1996;34:105-117.
25. Todhunter RJ, Yeager AE, Freeman KP, et al. Keratan sulfate as a marker of articular cartilage catabolism and joint treatment in ponies. Am J Vet Res 1993;54:1007-1016.
26. Metcalf MR, Twardock AR, Sanecki RK. 99m Tc-MDP Combined blood pool and bone phase radionuclide imaging in papain-injected carpal joints. Vet Radiol 1985;26:106-116.
27. Harbert JC. The musculoskeletal system. In: Harbert JC, Eckelman WC, Neumann RD, eds. Nuclear medicine diagnosis and therapy. New York: Thieme Medical Publishers Inc, 1996;801-880.
28. Innes JF, Barr ARS, Patterson MW, et al. Scintigraphy in the evaluation of osteoarthritis of the canine stifle joint. Vet Comp Orthop Traumatol. 1996;9:53-59.
29. McCrae F, Shouls J, Dieppe P, et al. Scintigraphic assessment of osteoarthritis of the knee joint. Ann Rheum Dis 1992;51:938-942.
30. Christensen SB. Osteoarthrosis. Changes of bone, cartilage and synovial membrane in relation to bone scintigraphy. Acta Orthop Scand Suppl 1985;56:1-43.
31. McNamara PS, Barr SC, Erb HN. Hematologic, hemostatic, and biochemical effects in dogs receiving an oral chondroprotective agent for thirty days. Am J Vet Res 1996;57:1390-1394.
32. Burkhardt D, Gosn P. Laboratory evaluation of antiarthritic drugs as potential chondroprotective agents. Semin Arthritis Rheum 1987;17:3-34.
33. Setnikar I, Cerada R, Pacinic MA, et al. Anti-reactive properties of glucosamine sulfate. Arzneimittleforshung 1991;157-161.
34. Rovetta G. Galatosaminoglycuronoglycan sulfate matrix in therapy of tibiofibular osteoarthritis of the knee. Drugs Exp Clin Res 1991;17:53-57.
35. Rejholec Y. Long-term studies of antiosteoarthritic drugs, an assessment. Semin Arthritis Rheum 1987;17(suppl): 1-35.
36. Moore M. Promising responses to a new oral treatment for degenerative joint disorders. Canine Pract 1996;21:7-11.
37. Hanson RR. Oral glycosaminoglycans in the treatment of degenerative joint disease in horses. Equine Pract 1996;18:18-21.
38. Hungerford DS. Treating osteoarthritis with chondroprotective agents. Orthopedic Special Ed 1998;4:39-42.
39. Boothe DM. Nutraceuticals in veterinary medicine. Part I. Compend Contin Educ Pract Vet 1997;19:1248-1255.
40. Boothe DM. Nutraceuticals in veterinary medicine. Part II. Compend Contin Educ Pract Vet 1998;20:15-21.
41. Davis WM. The role of glucosamine and chondroitin sulfate in the management of arthritis. Drug Topics 1998(suppl):3-13.